GlycoMimetics (NASDAQ:GLYC) Research Coverage Started at StockNews.com

Posted by Paula Ricardo on Mar 17th, 2025

StockNews.com started coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a report published on Friday morning. The firm issued a sell rating on the biotechnology company’s stock.

GlycoMimetics Trading Up 1.6 %

NASDAQ:GLYC opened at $0.26 on Friday. GlycoMimetics has a 1 year low of $0.14 and a 1 year high of $3.18. The firm has a 50 day moving average of $0.27 and a 200-day moving average of $0.25.

GlycoMimetics (NASDAQ:GLYC – Get Free Report) last posted its earnings results on Thursday, February 13th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. On average, equities research analysts predict that GlycoMimetics will post -0.08 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of GLYC. Jefferies Financial Group Inc. bought a new position in GlycoMimetics in the 4th quarter worth approximately $106,000. VR Adviser LLC bought a new position in GlycoMimetics in the 4th quarter worth approximately $747,000. Caxton Corp bought a new position in GlycoMimetics in the 4th quarter worth approximately $51,000. Adage Capital Partners GP L.L.C. bought a new position in GlycoMimetics in the 4th quarter worth approximately $1,268,000. Finally, ADAR1 Capital Management LLC raised its position in GlycoMimetics by 626.1% in the 4th quarter. ADAR1 Capital Management LLC now owns 331,827 shares of the biotechnology company’s stock worth $83,000 after purchasing an additional 286,127 shares during the last quarter. Institutional investors own 75.19% of the company’s stock.

GlycoMimetics Company Profile

(Get Free Report)

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.